The schizophrenia drug-treatment paradox: Pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries

British Journal of Psychiatry

Volumn 189, Issue NOV., 2006, Pages 391-392

  Adams, Clive E ^a   Tharyan, Prathap ^b   Coutinho, Evandro S F ^c   Stroup, T Scott ^d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c Ozwaldo Cruz Foundation   (Brazil)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

DRUG INDUSTRY; DRUG MARKETING; HUMAN; LONG TERM CARE; LOWEST INCOME GROUP; MENTAL HEALTH; REVIEW; SCHIZOPHRENIA;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; SCHIZOPHRENIA;

EID: 33750592550     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.106.029983     Document Type: Review

References (15)

1. Chalmers, I. (2006) From optimism to disillusion about commitment to transparency in the medico-industrial complex. Journal of the Royal Society of Medicine, 99, 337-341.
2. Easterbrook, P. J., Berlin, J. A., Gopalan, R., et al (1991) Publication bias in clinical research. Lancet, 337, 867-872.
3. Freeman, H. (1958) The tranquilising drugs. In Schizophrenia: A Review of the Syndrome (ed. L. Bellak), pp. 473-500. New York: Logos Press.
4. Gilbody, S. M., Song, F., Eastwood, A. J., et al (2000) The causes, consequences and detection of publication bias in psychiatry. Acta Psychiatrica Scandinavica, 102, 241-249.
5. Heres, S., Davis, J., Maino, K., et al (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysts of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry, 163, 185-194.
6. IMS Health Inc. (2006) IMS Health. http://www.imshealth.com/ims/portal/ front/articleC/0,2777,6025_3665_69890098,00.html
7. Joy, C. B., Adams, C. E. & Lawrie, S. M. (2001) Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, issue 2. Oxford: Update Software.
8. Lewis, S. W., Barnes, T. R., Davies, L., et al ( 2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin, 32, 715-723.
9. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
10. McGough, R. & Abboud, L. (2005) Lilly plans charge for Zyprexa accord. Wall Street Journal, 10 June, A3.
11. Moll, C., Gessler, U., Bartsch, S., et al (2003) Gross Domestic Product (GDP) and productivity of schizophrenia trials: an ecological study. BMC Psychiatry, 3, 18.
12. Montgomery, J. H., Byerly, M., Carmody, T., et al (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials, 25, 598-612.
13. Moynihan, R. (2003a) Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ, 326, 1189-1192.
14. Moynihan, R. (2003b) Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ, 326, 1193-1196.
15. Sackett, D. L., Richardson, W. S. & Rosenberg, W. (1997) Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingstone.